Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Болезнь Гоше у детей
Болезнь Гоше у детей
Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Полный текст
Список литературы
1. Baldellou A, Andria G, Campbell PE et al. Paediatric non-neuronopathic Gaucher disease: recommendations for treatment and monitoring. Eur J Pediatr 2004; 163 (2): 67–75.
2. Charrow J, Andersson HC, Kaplan P et al. Enzyme replacement therapy and monitoring for children with type 1 Gaucher disease: consensus recommendations. J Pediatr 2004; 144 (1): 112–20.
3. Charrow J, Esplin JA, Gribble TJ et al. Gaucher disease: recommendations on diagnosis, evaluation, and monitoring. Arch Intern Med 1998; 158 (16): 1754–60.
4. Grabowski GA, Hopkin RJ. Enzyme therapy for lysosomal storage disease: Principles, practice, and prospects. Annu Rev Genomics Hum Genet 2003; 4: 403–36.
5. Grabowski GA, Horowitz M. Gaucher's disease: molecular, genetic, and enzymological aspects. Baillieres Clin Haematol 1997; 10: 635–56.
6. Meikle PJ, Hopwood JJ, Clague AE, Carey WF. Prevalence of lysosomal storage disorders. JAMA 1999; 281: 249–54.
7. Pastores GM, Barnett NL, Bathan P et al. A neurological symptom survey of patients with type 1 Gaucher disease. J Inherit Metab Dis 2003; 26: 641–5.
8. Pastores GM, Weinreb NJ, Aerts H et al. Therapeutic goals in the treatment of Gaucher disease. Supp Semin Hematol 2004; 41 (4): 4–14.
9. Vellodi A, Bembi B, Villemeur TB et al. Neuronopathic Gaucher disease task force of the European working group on Gaucher disease. Management of neuronopathic Gaucher disease: a European consensus. J Inherit Metab Dis 2001; 24: 319–27.
10. Weinreb NJ, Deegan P, Kacena KA et al. Life expectancy in Gaucher disease type 1. Am J Hematol 2008; 83: 896–900.
2. Charrow J, Andersson HC, Kaplan P et al. Enzyme replacement therapy and monitoring for children with type 1 Gaucher disease: consensus recommendations. J Pediatr 2004; 144 (1): 112–20.
3. Charrow J, Esplin JA, Gribble TJ et al. Gaucher disease: recommendations on diagnosis, evaluation, and monitoring. Arch Intern Med 1998; 158 (16): 1754–60.
4. Grabowski GA, Hopkin RJ. Enzyme therapy for lysosomal storage disease: Principles, practice, and prospects. Annu Rev Genomics Hum Genet 2003; 4: 403–36.
5. Grabowski GA, Horowitz M. Gaucher's disease: molecular, genetic, and enzymological aspects. Baillieres Clin Haematol 1997; 10: 635–56.
6. Meikle PJ, Hopwood JJ, Clague AE, Carey WF. Prevalence of lysosomal storage disorders. JAMA 1999; 281: 249–54.
7. Pastores GM, Barnett NL, Bathan P et al. A neurological symptom survey of patients with type 1 Gaucher disease. J Inherit Metab Dis 2003; 26: 641–5.
8. Pastores GM, Weinreb NJ, Aerts H et al. Therapeutic goals in the treatment of Gaucher disease. Supp Semin Hematol 2004; 41 (4): 4–14.
9. Vellodi A, Bembi B, Villemeur TB et al. Neuronopathic Gaucher disease task force of the European working group on Gaucher disease. Management of neuronopathic Gaucher disease: a European consensus. J Inherit Metab Dis 2001; 24: 319–27.
10. Weinreb NJ, Deegan P, Kacena KA et al. Life expectancy in Gaucher disease type 1. Am J Hematol 2008; 83: 896–900.
Авторы
О.С.Гундобина
Научный центр здоровья детей РАМН, Москва
Научный центр здоровья детей РАМН, Москва
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.